Daniel Eiger

8PUBLICATIONS
26CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 08, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.

Diogo Martins-Branco, Marie Kassapian, Véronique Debien

|Jun 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

Jens Huober, Carlos H Barrios, Naoki Niikura

|Jun 10, 2022
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.

Chau Dang, Michael S Ewer, Suzette Delaloge

|Apr 03, 2021
The Exciting New Field of HER2-Low Breast Cancer Treatment.

Daniel Eiger, Elisa Agostinetto, Rita Saúde-Conde

|Mar 20, 2020
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Daniel Eiger, Mariana Brandão, Evandro de Azambuja

|Mar 14, 2020
The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC).

Daniel Eiger, Marcio Wagner, Noam F Pondé

Pageof 2

Frequent Collaborators

4 joint publications

Evandro de Azambuja

1 joint publications

Daniel Arcuschin de Oliveira

1 joint publications

Renato Leão de Oliveira

1 joint publications

Murilo Costa Sousa